Bioarray Granted Patent for Lead Breast Cancer Predictive Test

Share Article

Test is used for predicting the efficacy of breast cancer treatments.

News Image
This test exemplifies the impact of advanced molecular testing on breast cancer treatment.

Bioarray Genetics, Inc.("Bioarray" or the "Company") announced today that the Company has been granted a US patent supporting its lead breast cancer predictive test.

The US Patent & Trademark Office has issued US Patent No. 9,771,618 "Clinical tests for testing therapeutic sensitivity of cancerous breast tissue and methods and kits for performing the same," which covers genes and algorithms used to predict patient response to taxane-based chemotherapy treatments. Specifically, the patent covers methods and kits for predicting the efficacy of treatment of breast cancer comprising the analysis of an expression profile of marker genes from cancerous breast tissue and predicting the efficacy of treatment if the expression profile from the cancerous breast tissue matches a predetermined expression profile, indicating the patient’s response to the treatment. Additionally, the method described further generates a report indicating the likelihood of long-term survival with breast cancer recurrence in the patient.

Early detection of cancer is vital for patient survival by increasing treatment options. Breast cancer ranks as the second leading cause of death among women with cancer in the United States and early detection of breast cancer has a significant impact on patient survival. As such, identifying patient response to a form of therapy at the beginning of the treatment decision-making process can have considerable impact on patient outcomes and health economics.

Marcia Fournier, the founder and CEO of Bioarray notes, “Bioarray’s lead test is the first of a pipeline of predictive tests that can provide actionable information to physicians to improve the decision-making process for cancer treatments and enhanced outcomes. The test provides information on treatment response, but is also able to identify those triple negative breast cancer patients with the worst survival rates,” she adds, “This test exemplifies the impact of advanced molecular testing on breast cancer treatment.”

Bioarray BA100 test will be available to physicians and patients in 2018.

About Bioarray Genetics

Bioarray Genetics, Inc., a molecular diagnostics company, is focused on the development of predictive test that provide actionable information to clinicians in the treatment planning process for cancer patients to eliminate the trial and error approach to treatment. The company’s gene profiling platform serves as the foundation for the development of predictive tests that can be used for treatment planning, companion diagnostics, and drug research and development. The company’s pipeline of tests includes a predictive test for metastatic breast and colon cancers. Bioarray is a privately held company based in Farmington, CT. For more information on Bioarray, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Pamela Layton
+1 781-254-2580
Email >
Visit website